Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$58.92 - $84.67 $15.1 Million - $21.6 Million
-255,525 Reduced 98.61%
3,591 $222,000
Q2 2022

Aug 05, 2022

SELL
$79.4 - $116.36 $7.18 Million - $10.5 Million
-90,470 Reduced 25.88%
259,116 $20.7 Million
Q1 2022

May 13, 2022

BUY
$86.42 - $109.81 $955,286 - $1.21 Million
11,054 Added 3.27%
349,586 $36.8 Million
Q4 2021

Feb 14, 2022

SELL
$98.56 - $119.91 $338,356 - $411,651
-3,433 Reduced 1.0%
338,532 $36.5 Million
Q3 2021

Nov 12, 2021

BUY
$91.91 - $110.37 $894,284 - $1.07 Million
9,730 Added 2.93%
341,965 $37.5 Million
Q2 2021

Aug 13, 2021

BUY
$86.24 - $95.92 $1.08 Million - $1.2 Million
12,508 Added 3.91%
332,235 $31.1 Million
Q1 2021

May 17, 2021

SELL
$71.83 - $95.48 $1.31 Million - $1.73 Million
-18,168 Reduced 5.38%
319,727 $29.4 Million
Q4 2020

Feb 12, 2021

SELL
$67.0 - $84.39 $117,384 - $147,851
-1,752 Reduced 0.52%
337,895 $24.7 Million
Q3 2020

Nov 12, 2020

SELL
$55.23 - $79.93 $8.39 Million - $12.1 Million
-151,904 Reduced 30.9%
339,647 $26.4 Million
Q2 2020

Aug 14, 2020

SELL
$30.2 - $56.98 $27.6 Million - $52 Million
-912,729 Reduced 65.0%
491,551 $27.3 Million
Q1 2020

May 15, 2020

BUY
$24.87 - $38.56 $21,189 - $32,853
852 Added 0.06%
1,404,280 $41.6 Million
Q4 2019

Feb 14, 2020

SELL
$25.43 - $36.67 $959,575 - $1.38 Million
-37,734 Reduced 2.62%
1,403,428 $50.8 Million
Q3 2019

Nov 13, 2019

BUY
$23.0 - $27.97 $5.88 Million - $7.15 Million
255,461 Added 21.55%
1,441,162 $39.2 Million
Q2 2019

Aug 14, 2019

BUY
$22.81 - $28.48 $27 Million - $33.8 Million
1,185,701 New
1,185,701 $28.5 Million

Others Institutions Holding HZNP

About Horizon Therapeutics Public Ltd Co


  • Ticker HZNP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 230,384,000
  • Description
  • Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...
More about HZNP
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.